Literature DB >> 7036280

A randomized trial of postoperative five-versus three-drug chemotherapy after mastectomy: a Cancer and Leukemia Group B (CALGB) study.

R B Weiss, D C Tormey, F Holland, V E Weinberg, G Lesnick, M Perloff, G Falkson, O J Glidewell.   

Abstract

The Cancer and Leukemia Group B (CALB) has conducted a randomized study of adjuvant chemotherapy in patients with breast cancer who have involved axillary nodes at the time of mastectomy. Five-drug treatment (CMFVP) was compared with three-drug treatment (CMF). For patients with more than three involved nodes, the CMFVP regimen produced a significantly prolonged disease-free survival in comparison to the CMF regimen.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7036280     DOI: 10.1007/978-3-642-81685-7_28

Source DB:  PubMed          Journal:  Recent Results Cancer Res        ISSN: 0080-0015


  3 in total

1.  Postmastectomy adjuvant chemotherapy with or without radiation therapy in women with operable breast cancer and positive axillary lymph nodes: the Southeastern Cancer Study Group experience.

Authors:  E Velez-Garcia; M Moore; C L Vogel; V Marcial; A Ketcham; A Bartolucci; C Liu; R Smalley
Journal:  Breast Cancer Res Treat       Date:  1983       Impact factor: 4.872

2.  Cancer and Leukemia Group B adjuvant chemotherapy trials in postmastectomy breast cancer patients.

Authors:  W C Wood
Journal:  Breast Cancer Res Treat       Date:  1983       Impact factor: 4.872

3.  Lomustine is beneficial to older AML with ELN2017 adverse risk profile and intermediate karyotype: a FILO study.

Authors:  Laetitia Largeaud; Pascale Cornillet-Lefebvre; Jean-François Hamel; Christian Récher; Arnaud Pigneux; Eric Delabesse; Pierre-Yves Dumas; Naïs Prade; Stéphanie Dufrechou; Julien Plenecassagnes; Isabelle Luquet; Odile Blanchet; Anne Banos; Marie C Béné; Marc Bernard; Sarah Bertoli; Caroline Bonmati; Luc Matthieu Fornecker; Romain Guièze; Lamya Haddaoui; Mathilde Hunault; Jean Christophe Ianotto; Eric Jourdan; Mario Ojeda; Pierre Peterlin; Norbert Vey; Hacene Zerazhi; Hicheri Yosr; Ariane Mineur; Jean-Yves Cahn; Norbert Ifrah
Journal:  Leukemia       Date:  2020-09-18       Impact factor: 12.883

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.